No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

(Repeats Feb 16 story with no changes to text) By Medha Singh and Manas Mishra (Reuters) - U.S.-based Eli Lilly (NYSE:LLY) and... By Medha Singh and Manas Mishra (Reuters) - U.S.-based Eli Lilly ...

Overview: Zealand Pharma A/S is a biotechnology company focused on discovering, developing, and commercializing peptide-based medicines in Denmark and the United States, with a market capitalization ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...